New combo therapy could protect kidneys and hearts without High-Dose statins

NCT ID NCT07524101

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two cholesterol-lowering strategies in about 1,950 adults with chronic kidney disease and heart or blood vessel disease. One group gets a moderate-dose statin plus ezetimibe, the other gets a high-dose statin alone. The goal is to see if the combo is just as good at preventing heart attacks, strokes, and other major events, while being safer for the kidneys. Participants will be followed for three years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease cardiovascular disorder chronic kidney disease Dyslipidemias Hypercholesterolemia hyperlipidemia inherited lipid metabolism disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS CARDIOVASCULAR DISEASES DYSLIPIDEMIA HYPERCHOLESTEROLEMIA RENAL INSUFFICIENCY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Severance Hospital
RECRUITING

Seoul, 03722, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.